Congenital Hyperinsulinism Treatment Market Outlook 2032
The global congenital hyperinsulinism treatment market size was USD 154.5 Million in 2023 and is projected to reach USD 254.4 Million by 2032, expanding at a CAGR of 5.7% during 2024–2032. The market growth is attributed to the increasing prevalence of congenital hyperinsulinism across the globe.
Increasing awareness of congenital hyperinsulinism (CHI) is resulting in a high demand for CHI treatment solutions, which further boosts the market. Advances in genetic testing technologies enable the identification of specific genetic mutations underlying CHI, allowing for targeted interventions that optimize treatment efficacy and minimize adverse effects. Moreover, the rising demand for personalized medicine and targeted therapies tailored to specific genetic mutations associated with CHI further boosts the market during the forecast period.
-
According to a report published by the National Library of Medicine on January 31, 2023, the number of drugs with personalized indications for their use increased by 70% between 2015 and 2020.
Impact of Artificial Intelligence (AI) in the Congenital Hyperinsulinism Treatment Market
The use of artificial intelligence is likely to boost the congenital hyperinsulinism treatment market. AI algorithms analyze large datasets of patient information, genetic data, and clinical outcomes to identify patterns and personalize treatment plans for individuals with CHI. Additionally, AI-powered diagnostic tools enhance early detection of CHI by analyzing medical images and biochemical markers with high accuracy and efficiency.
Congenital Hyperinsulinism Treatment Market Dynamics
Major Drivers
Increasing prevalence of congenital hyperinsulinism (CHI) is anticipated to drive the market during the forecast period. Rising awareness among healthcare professionals and the general population regarding to the rising incidence of CHI boost the market. For instance, as per the report published by the National Organization of Rare Disorders on March 24, 2020, Congenital hyperinsulinism (HI) occurs in approximately One out of every 25,000 to 50,000 births in majority of countries. Additionally, the growing emphasis on early diagnosis and treatment of CHI to prevent long-term complications further contributes to the market growth.
Existing Restraints
High treatment costs are expected to hamper the market during the forecast period. The complex nature of CHI and the need for lifelong management often involve multiple expansive treatment modalities, including medications, surgical interventions, and specialized monitoring equipment. Furthermore, the limited awareness and underdiagnosis of congenital hyperinsulinism (CHI) further hinder the market.
Emerging Opportunities
Continuous advancements in congenital hyperinsulinism treatment technology are expected to create immense opportunities for the players competing in the market in the coming years. Pharmaceutical companies are focusing on developing innovative therapeutic approaches to address the complex needs of patients with this rare genetic disorder. These advancements span various aspects of treatment, including novel drug formulations, targeted therapies, gene therapy, and personalized medicine approaches. Moreover, the integration of cutting-edge technologies, such as genomic sequencing, and molecular diagnostics enhances the accuracy of diagnosis and facilitates personalized treatment strategies, further boosting the demand.
Scope of the Congenital Hyperinsulinism Treatment Market Report
The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics are included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Congenital Hyperinsulinism Treatment Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2023
|
|
Historic Data
|
2017 -2022
|
|
Forecast Period
|
2024–2032
|
|
Segmentation
|
Drug Type (Octreotide, Diazoxide, Nifedipine, Glucagon, and Others), Route of Administration (Parenteral and Oral), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Crinetics Pharmaceuticals, Inc; Novartis Pharmaceuticals Corporation; Zealand Pharma A/S; Rezolute, Inc; Hanmi Pharm.Co.,Ltd; and Teva Pharmaceutical Industries Ltd.
|
Congenital Hyperinsulinism Treatment Market Segment Insights
Drug Segment Analysis
Based on drug type, the congenital hyperinsulinism treatment market is divided into octreotide, diazoxide, nifedipine, glucagon, and others. The diazoxide segment held a major share of the market in 2023, due to their widespread use as a first-line treatment for congenital hyperinsulinism (CHI).
Diazoxide acts by inhibiting insulin secretion from pancreatic beta cells, helping maintain blood glucose levels within the normal range. Moreover, the availability of generic formulations of diazoxide has contributed to its accessibility and affordability, further boosting the segment.
The glucagon segment is expected to expand at a significant growth rate in the coming years, owing to the increasing importance of glucagon in managing CHI-related hypoglycemia. Glucagon is used as an emergency treatment to counteract severe hypoglycemia episodes that are unresponsive to other therapies. Furthermore, the development of novel glucagon analogs with improved stability and enhanced treatment efficacy in CHI further boosts the segment.
Route of Administration Segment Analysis
On the basis of route of administration, the global market is segregated into parenteral and oral. The parenteral segment held largest market share in 2023, as they offer rapid and reliable delivery of medications to manage hypoglycemia in patients with congenital hyperinsulinism (CHI).
Parenteral administration allows for the direct and immediate delivery of medications, such as diazoxide and glucagon to stabilize blood glucose levels during hypoglycemic crises. Moreover, healthcare professionals often prefer parenteral routes for CHI treatment in emergency settings for their rapid onset of action, thereby boosting their demand in various healthcare settings.
The oral route segment is anticipated to expand at a substantial CAGR during the forecast period, owing to their convenience and improved medication adherence for long-term maintenance therapy in CHI patients. Oral formulations of medications provide a non-invasive and easily accessible treatment option for managing CHI-related hyperinsulinemia and hypoglycemia. Furthermore, advancements in extended-release formulations and taste-masking techniques enhancing the palatability and tolerability of oral medications, further boost their adoption in CHI management.
Distribution Channel Segment Analysis
Based on distribution channel, the congenital hyperinsulinism treatment market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others. The online pharmacies segment is projected to register a robust growth rate during the assessment years, as they provide the convenience of receiving doorstep delivery to eliminate frequent visits to physical pharmacies. Moreover, e-pharmacy often offers competitive pricing and discounts on medications, making them an attractive option for patients seeking affordable CHI treatments.
Regional Outlook
In terms of region, the global congenital hyperinsulinism treatment market is classified as Asia Pacific, North America, Latin America, Europe, and the Middle East & Africa. North America held a major market share in 2023, due to the high adoption of novel therapies and robust research and development activities in the field of rare diseases. Moreover, increasing awareness among healthcare professionals and the general population about CHI and its management options further fuels the market.
The market in Asia Pacific is projected to grow at a significant pace in the years to come, owing to the increasing prevalence of CHI and rising healthcare expenditure in emerging economies. For instance, the report published by the WHO in 2022 revealed that before the COVID-19 pandemic between 2010 and 2019, low- and lower-middle-income countries in the region experienced a 65% increase in per capita health spending, while upper-middle-income countries grew by 76% during the same period. Furthermore, advancements in genetic testing technologies are likely to facilitate early diagnosis and prompt initiation of CHI treatment in the region.
Segments
The congenital hyperinsulinism treatment market has been segmented on the basis of
Drug Type
- Octreotide
- Diazoxide
- Nifedipine
- Glucagon
- Others
Route of Administration
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
Competitive Landscape
Key players competing in the global congenital hyperinsulinism treatment market are Crinetics Pharmaceuticals, Inc; Novartis Pharmaceuticals Corporation; Zealand Pharma A/S; Rezolute, Inc; Hanmi Pharm.Co.,Ltd; and Teva Pharmaceutical Industries Ltd.
These companies employ development strategies such as mergers, acquisitions, partnerships, collaborations, and product launches to broaden their consumer base globally. For instances,
-
In December 2023, Denmark-based biotechnology research company, Zealand Pharma A/S, announced that the FDA had rejected their application for the use of dasiglucagon. The request was made by the company to use dasiglucagon for the prevention and treatment of hypoglycemia in pediatric patients with congenital hyperinsulinism (CHI) who are at least seven days old. The proposed dosing schedule was for a maximum of three weeks.
Request For Customization
Enquiry Before Buying
Speak With Analyst
